Evidence map›Paper›PMID 37966546›Full record

Trial reportMedical oncology (Northwood, London, England)2023

Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study.

Shichao Li, Dongxiao Shen, Qingsong Zuo, Shengzi Wang, Lingjia Meng, Jiaojiao Yu, Yang Liu, Wusheng Li, Chao Chen, Peihao Yin and 2 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shichao Li *Anorectal Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China.
Dongxiao Shen *General Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qingsong ZuoGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shengzi WangGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Lingjia MengGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jiaojiao YuGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yang LiuGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wusheng LiAnorectal Department, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China.
Chao ChenGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Peihao YinGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Teng ChenGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. 13801842406@163.com.
Jie WangGeneral Surgery Department, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. wangjie4177@126.com.ORCID http://orcid.org/0009-0002-8440-4725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although some studies in China have suggested Huachansu (HCS) combined with chemotherapy is effective in the treatment of various cancers, there are few studies on colorectal cancer (CRC), especially in postoperative adjuvant chemotherapy. The aim of this study was to test the hypothesis that HCS combined with adjuvant chemotherapy would improve survival probability in resected CRC patients. This was a prospective, open-label, randomized phase II study. Patients with stage III or high-risk stage II resected CRC were randomly assigned to the chemotherapy and HCS + chemotherapy groups. The Chemotherapy group was treated with the FOLFOX regimen for ≥ 6 cycles or the CAPEOX regimen for ≥ 4 cycles. The HCS + chemotherapy group was treated with HCS on the basis of the chemotherapy group. The primary endpoint was 3-year disease-free survival (DFS), and the secondary endpoints were 3-year overall survival (OS) and toxicity. A total of 250 patients were included in this study (126 chemotherapy, 124 HCS + chemotherapy). There were significant differences in 3-year DFS between the two groups (median 28.7 vs. 31.6 months, respectively; P = 0.027), but no significant differences in 3-year OS between the two groups (median 32.7 vs. 34 months, respectively; P = 0.146). No patients experienced grade four adverse events, and the rates of leukopenia, neutropenia, and diarrhea in the HCS + chemotherapy group were lower than that those in the chemotherapy group. HCS combined with adjuvant chemotherapy after radical resection for patients with stage III or high-risk stage II CRC was demonstrated to be an effective and feasible treatment.

Indexed as

Amphibian VenomsColorectal NeoplasmsChemotherapy, AdjuvantHumansProspective StudiesAmphibian VenomshuachansuAdjuvant chemotherapyClinical trialColorectal cancerHuachansu

Identifiers

PMID37966546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.